![Autism And Cbd: What Science Says About Hemp Therapy [FItVIfuYe3z]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/09/ced-pexels-13091435.jpg?resize=150%2C150&ssl=1 "Autism And Cbd: What Science Says About Hemp Therapy [FItVIfuYe3z] 26")
Clinical Takeaway
VER-01, a full-spectrum extract from Cannabis sativa DKJ127, demonstrated efficacy and safety in treating chronic low back pain compared to placebo. The study showed significant improvements in pain relief and functional outcomes without major adverse effects.
#2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
What This Study Teaches Us
A full-spectrum cannabis extract (VER-01) reduced chronic low back pain by about 0.6 points on a 0-10 scale more than placebo over 12 weeks, with additional benefit in people with neuropathic pain features. Effects were sustained and even improved over 6 months of open-label treatment, though withdrawal did show pain rebound favoring active treatment over placebo.
Why This Matters Clinically
Current treatments for chronic low back pain are either modestly effective or carry real risks. If this extract proves tolerable in routine use, it offers clinicians another option for patients who’ve failed or can’t tolerate standard care. The neuropathic pain signal is particularly relevant because that subset is notoriously hard to treat.
Study Snapshot
| Study Design | Multicenter randomized controlled trial with 12-week double-blind phase, 6-month open-label extension, then 6-month continuation or randomized withdrawal phase |
| Population | 820 adults with chronic low back pain (394 VER-01, 426 placebo). Demographics and other baseline characteristics not specified in abstract. |
| Intervention | VER-01, a full-spectrum Cannabis sativa extract from strain DKJ127. Specific dose, formulation, and cannabinoid profile not specified in abstract. |
| Primary Outcome | Change in numeric rating scale (NRS) pain intensity (0-10) over 12 weeks. Key secondary outcome was neuropathic pain symptom inventory (NPSI) score in participants with neuropathic features (PainDETECT > 18). |
| Key Result | Phase A: VER-01 reduced pain by 1.9 NRS points versus 1.3 for placebo (difference 0.6, p < 0.001). NPSI decreased by 14.4 points in VER-01 versus 7.1 in placebo (difference 7.3, p = 0.017). Withdrawal phase did not meet significance but showed greater pain rebound with placebo. |
Where This Paper Deserves Skepticism
The 0.6-point difference in pain reduction, while statistically significant, sits at the borderline of clinically meaningful change and could reflect publication of a positive trial in a high-profile journal without knowing how many sites or trials were screened. The abstract doesn’t tell us the cannabinoid content, dose escalation protocol, or how adverse events were distributed (83.3% rate in VER-01 sounds high and deserves scrutiny of what exactly was counted). The generalizability to typical primary care populations is unclear without baseline demographics. The withdrawal phase’s failure to meet its primary endpoint formally weakens the case for long-term benefit, though the post-hoc pain rebound finding is suggestive.
Dr. Caplan’s Take
This is a genuinely solid phase 3 trial showing that a cannabis extract does something measurable for low back pain, with a signal in the neuropathic subgroup that I find clinically interesting. The effect size is modest but real, and the safety profile in phase A looked manageable enough to warrant open-label continuation. What I’d want before prescribing is the full paper: What’s actually in this extract? What was the dose? What were those adverse events and how many people stopped? And does this apply to my patients or just the German population studied here? I’m not dismissing this, but I’m also not reading it as ‘cannabis solves back pain.’ It’s one tool that helped some people in a controlled setting.
Clinical Bottom Line
A full-spectrum cannabis extract showed modest but statistically significant benefit over placebo for chronic low back pain over 12 weeks. Before integrating this into practice, clinicians need the full paper to understand dosing, safety profile, and generalizability to their population.
| |
Have thoughts on this? Share it:
